Search

Over a period of seven years (from 1980 to 1987) 58 acute viral hepatitis A cases were admitted to the Departments for Infectious Diseases. This number represents 10.76% of all viral hepatitis patients. Most of the patients had travelled to foreign countries or to areas in Italy with high hepatitis A virus (HAV) circulation. An assessment of specific immunization against HAV in normal healthy people aged 1-60, performed by ELISA, showed a very low number of sero-positive subjects. The disappearance of HAV in Italy, which is similar to other western European countries, is probably due to the improved socio-economical conditions; the "imported cases" seem to have little impact on public health.

Background: Several studies carried out in the USA and in Europe have shown the presence of HTLV-I/II antibodies in subjects belonging to high-risk groups for HIV infection as well as blood donors. Concern about the presence of HTLV-I/II markers in the normal population, as well as the efficient transmission of HTLV-I/II by whole blood or infected blood cells have led several countries to include screening for anti-HTLV-I/II among the mandatory serological testing of blood donors. Objective: In order to assess the risk of HTLV-I/II infection related to blood transfusions, a multicentric survey for antibodies against HTLV-I and HTLV-II was carried out involving 10 Italian sites during the spring of 1991. Study design: Serum specimens were collected from 14,598 blood donors, 1,411 injecting drug users, 1,015 thalassemics, 142 hemophiliacs and 138 hemodialysis patients. HTLV antibodies were detected by a screening EIA which combines a viral lysate with a recombinant HTLV-I env protein (p21e). The serological confirmation was performed by a semi-automated dot-blot immunoassay that detects gag p19 and p24 and env p21e specific antibodies, while the discrimination of HTLV-I and HTLV-II reactivities was carried out by EIAs employing synthetic peptides of the ENV region specific for each virus. Results: The seroprevalence of confirmed positives was 0.034% among blood donors and 3.61% among IDUs, while no sample of the other categories could be confirmed, although several were indeterminate and one thalassemic reacted against HTLV-I on peptide testing. HTLV-I reactivity was observed in one blood donor, while all 38 of the 51 confirmed seropositive IDU's reacted only to the HTLV-II synthetic peptide. Conclusions: These data confirm a high prevalence of HTLV-II among Italian IDUs and show an HTLV-I/II seroprevalence among blood donors very similar to that which was found in the USA volunteer blood donors. A surveillance program among blood donors seems advisable in order to establish the possible need of a mandatory screening for HTLV-I/II.

Synthetic octapeptides spanning the 119–147 region of the Hepatitis C Virus (HCV) CI00 protein were tested on HCV positive sera. The 138–145 region proved to be antigenic and possibly able to avoid undesired cross-reactions.

Ozone therapy has been used as a complementary medical approach for half a century but it has encountered skepticism by orthodox medicine because, particularly in the past, it has been used by practitioners and others without a rational basis and appropriate controls. With the advent of modern medical ozone generators incorporating a photometer, it has become possible to obtain precise ozone concentrations and to evaluate some mechanisms of action and possible toxicity. In contrast with the respiratory tract, human blood exposed to appropriate ozone concentrations is able to tame its strong oxidant properties and neither acute, nor chronic side effects have ensued in millions of patients treated with ozonated autohaemotherapy (O3-AHT). This review summarizes our studies aimed at clarifying biological effects, defining any possible damage, the therapeutic window and suitable doses able to express a therapeutic activity. A very interesting and promising aspect is the induction of the so-called heat...